Back to today’s briefing

Story perspectives

Transformative $30M Trial to Tackle Life-Threatening Seizures

2/15/2025

38 8

Summary

Story summary

A groundbreaking $30 million clinical trial, KESETT, is set to begin at the University of Virginia, testing ketamine's potential to treat status epilepticus, a life-threatening seizure disorder. With a generous $9.3 million NIH grant, this trial seeks to transform the lives of the 160,000 Americans, especially vulnerable children aged 1-17, who face this challenging condition each year.

1 of 1

Story summary

A groundbreaking $30 million clinical trial, KESETT, is set to begin at the University of Virginia, testing ketamine's potential to treat status epilepticus, a life-threatening seizure disorder. With a generous $9.3 million NIH grant, this trial seeks to transform the lives of the 160,000 Americans, especially vulnerable children aged 1-17, who face this challenging condition each year.